

08/25/00

35714 U.S. PTO



# UTILITY PATENT APPLICATION TRANSMITTAL

Only for new nonprovisional applications under 37 CFR 1.53(b)

Attorney Docket No.

5.1183

First Named Inventor or Application Identifier

Satoshi Koizumi, et al.

Express Mail Label No.

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

## ADDRESS TO:

Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☐ Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)

2. ☒ Specification Total Pages **38**

3. ☒ Drawing(s) (35 USC 113) Total Sheets **3**

4. ☒ Oath or Declaration Total Pages **2**

- a. ☒ Newly executed (original or copy)  
b. ☐ Unexecuted for information purposes

- c. ☐ Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]

- d. ☐ DELETION OF INVENTOR(S)

Signed Statement attached deleting  
inventor(s) named in the prior application, see  
37 CFR 1.63(d)(2) and 1.33(b).

5. ☐ Incorporation By Reference (useable if Box 4c is checked)  
The entire disclosure of the prior application, from which a copy of  
the oath or declaration is supplied under Box 4c, is considered as  
being part of the disclosure of the accompanying application and is  
hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)

- a. ☒ Computer Readable Copy  
b. ☒ Paper Copy (identical to computer copy)  
c. ☒ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☒ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application  
Statement(s) Status still proper and desired
15. ☒ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☒ Other: Claim to Priority

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No. 1

## 18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

05514

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

NAME

Address

City

State

Zip Code

Country

Telephone

Fax

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	28 -20 =	8	X \$ 18.00 =	\$144.00
	INDEPENDENT CLAIMS (37 cfr 1.16(b))	1 -3 =	0	X \$ 78.00 =	\$0.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			\$260.00 =	\$260.00
				BASIC FEE (37 CFR 1.16(a))	\$690.00
			Total of above Calculations = \$1094.00		
Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28)					
	TOTAL =				\$1094.00

## 19 Small entity status

- a. ☐ A Small entity statement is enclosed
- b. ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- c. ☐ Is no longer claimed.

20. ☒ A check in the amount of \$ 1094.00 to cover the filing fee is enclosed21. ☒ A check in the amount of \$ 40.00 to cover the recordal fee is enclosed.

## 22. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 06-1205

- a. ☒ Fees required under 37 CFR 1.16.
- b. ☒ Fees required under 37 CFR 1.17.
- c. ☐ Fees required under 37 CFR 1.18.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME **Lawrence S. Perry**  
Registration No. 31,865

SIGNATURE

DATE

August 25, 2000

# INVENTOR INFORMATION

Inventor One Given Name:: Satoshi  
Family Name:: Koizumi  
Postal Address Line One:: c/o Tokyo Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
Postal Address Line Two:: 6-6, Asahi-machi 3-chome  
City:: Machida-shi  
State or Province:: Tokyo 194-8533  
Country:: Japan

Inventor Two Given Name:: Kazuhiko  
Family Name:: Tabata  
Postal Address Line One:: c/o Technical Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
Postal Address Line Two:: 1-1, Kyowa-cho  
City:: Hofu-shi  
State or Province:: Yamaguchi 747-8522  
Country:: Japan

Inventor Three Given Name:: Tetsuo  
Family Name:: Endo  
Postal Address Line One:: c/o Tokyo Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
Postal Address Line Two:: 6-6, Asahi-machi 3-chome  
City:: Machida-shi  
State or Province:: Tokyo 194-8533  
Country:: Japan

Inventor Four Given Name:: Akio  
Family Name:: Ozaki  
Postal Address Line One:: c/o Technical Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
Postal Address Line Two:: 1-1, Kyowa-cho  
City:: Hofu-shi  
State or Province:: Yamaguchi 747-8522  
Country:: Japan

## CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 05514  
Fax:: (212) 218-2200

## APPLICATION INFORMATION

Title Line One:: PROCESS FOR PRODUCING N-ACETYLNEURAMINIC ACID  
Total Drawing Sheets:: 3  
Formal Drawings?: Yes  
Application Type:: Utility

1. **Introduction**  
 2. **Background**  
 3. **Methods**  
 4. **Results**  
 5. **Conclusion**  
 6. **References**  
 7. **Appendix**  
 8. **Figure**  
 9. **Table**  
 10. **Figure**  
 11. **Table**  
 12. **Figure**  
 13. **Table**  
 14. **Figure**  
 15. **Table**  
 16. **Figure**  
 17. **Table**  
 18. **Figure**  
 19. **Table**  
 20. **Figure**  
 21. **Table**  
 22. **Figure**  
 23. **Table**  
 24. **Figure**  
 25. **Table**  
 26. **Figure**  
 27. **Table**  
 28. **Figure**  
 29. **Table**  
 30. **Figure**  
 31. **Table**  
 32. **Figure**  
 33. **Table**  
 34. **Figure**  
 35. **Table**  
 36. **Figure**  
 37. **Table**  
 38. **Figure**  
 39. **Table**  
 40. **Figure**  
 41. **Table**  
 42. **Figure**  
 43. **Table**  
 44. **Figure**  
 45. **Table**  
 46. **Figure**  
 47. **Table**  
 48. **Figure**  
 49. **Table**  
 50. **Figure**  
 51. **Table**  
 52. **Figure**  
 53. **Table**  
 54. **Figure**  
 55. **Table**  
 56. **Figure**  
 57. **Table**  
 58. **Figure**  
 59. **Table**  
 60. **Figure**  
 61. **Table**  
 62. **Figure**  
 63. **Table**  
 64. **Figure**  
 65. **Table**  
 66. **Figure**  
 67. **Table**  
 68. **Figure**  
 69. **Table**  
 70. **Figure**  
 71. **Table**  
 72. **Figure**  
 73. **Table**  
 74. **Figure**  
 75. **Table**  
 76. **Figure**  
 77. **Table**  
 78. **Figure**  
 79. **Table**  
 80. **Figure**  
 81. **Table**  
 82. **Figure**  
 83. **Table**  
 84. **Figure**  
 85. **Table**  
 86. **Figure**  
 87. **Table**  
 88. **Figure**  
 89. **Table**  
 90. **Figure**  
 91. **Table**  
 92. **Figure**  
 93. **Table**  
 94. **Figure**  
 95. **Table**  
 96. **Figure**  
 97. **Table**  
 98. **Figure**  
 99. **Table**  
 100. **Figure**

NY\_MAIN 106367 v 1

5.1183

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
SATOSHI KOIZUMI, ET AL. ) Examiner: Not Yet Assigned  
Application No.: N/Y/A ) Group Art Unit: N/Y/A  
Filed: Currently herewith )  
For: PROCESS FOR PRODUCING )  
N-ACETYLNEURAMINIC ACID : August 25, 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to action on the merits, please amend the  
above-identified application as follows:

IN THE CLAIMS:

Please amend Claims 6-11 as follows.

Claim 6, line 1, change "any of claims 1-5" to  
--claim 5--.

Claim 7, line 1, change "any of claims 1-6" to  
--claim 5--.

Claim 8, line 1, change "any of claims 1-7" to  
--claim 5--.

Claim 9, line 1, change "any of claims 1-8" to  
--claim 5--.

Claim 10, line 1, change "any of claims 6-9" to  
--claim 6--.

Claim 11, line 1, delete "8 or 9,".

Please add the following new claims 12-16.

--12. The process according to claim 7, wherein  
said microorganism belonging to the genus Escherichia is  
Escherichia coli.

13. The process according to claim 8, wherein said  
microorganism belonging to the genus Escherichia is  
Escherichia coli.

14. The process according to claim 9, wherein said  
microorganism belonging to the genus Escherichia is  
Escherichia coli.

15. The process according to claim 8, wherein said  
microorganism belonging to the genus Corynebacterium is  
Corynebacterium ammoniagenes, Corynebacterium glutamicum or  
Corynebacterium acetoacidophilum.

16. The process according to claim 9, wherein said microorganism belonging to the genus Corynebacterium is Corynebacterium ammoniagenes, Corynebacterium glutamicum or Corynebacterium acetoacidophilum.--


REMARKS

Claims 6-11 have been amended to correct their dependency and conformity with accepted U.S. practice. No new matter has been added.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

  
\_\_\_\_\_  
Attorney for Applicants  
Lawrence S. Perry  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

LSP\ac

NY\_MAIN 106384 v.1

APPLICATION FOR PATENT

Inventors: 1. Satoshi Koizumi  
2. Kazuhiko Tabata  
3. Tetsuo Endo  
4. Akio Ozaki

Citizens of: Japan

Post Office  
Address:

1. c/o Tokyo Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
6-6, Asahi-machi 3-chome  
Machida-shi, Tokyo 194-8533 Japan
2. c/o Technical Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
1-1, Kyowa-cho, Hofu-shi, Yamaguchi  
747-8522 Japan
3. c/o Tokyo Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
6-6, Asahi-machi 3-chome  
Machida-shi, Tokyo 194-8533 Japan
4. c/o Technical Research Laboratories  
KYOWA HAKKO KOGYO CO., LTD.  
1-1, Kyowa-cho, Hofu-shi, Yamaguchi  
747-8522 Japan

Title: PROCESS FOR PRODUCING  
N-ACETYLNEURAMINIC ACID

00220-1225496



## PROCESS FOR PRODUCING N-ACETYLNEURAMINIC ACID

Background of the Invention

The present invention relates to a process for producing  
5 N-acetylneuraminic acid by using a microorganism having N-  
acetylneuraminic acid aldolase activity or N-acetylneuraminic  
acid synthetase activity.

It is known that N-acetylneuraminic acid can be produced  
by extraction, decomposition or by use of enzymes.

10 An example of a known method by extraction is extraction  
from a nest of sea swallows, etc. [Carbohydrate Research, 56,  
423 (1977)].

An example of a known method by decomposition is  
decomposition of colominic acid, which is an N-  
15 acetylneuraminic acid polymer produced by Escherichia coli,  
etc. [J. Biochem., 82, 1425 (1977)].

Known methods utilizing enzymes include the following:  
methods using N-acetylneuraminic acid aldolase, pyruvic acid  
and N-acetylmannosamine [J. Am. Chem. Soc., 110, 6481 (1988);  
20 J. Am. Chem. Soc., 110, 7159 (1988)]; a method using N-  
acetylneuraminic acid aldolase, pyruvic acid and N-  
acetylglucosamine under alkaline conditions (U.S. Patent No.  
5,665,574); methods using N-acetylneuraminic acid aldolase,  
N-acetylglucosamine 2-epimerase, pyruvic acid and N-  
25 acetylglucosamine [Angew. Chem. Int. Ed. Eng., 30, 827 (1991);  
Carbohydrate Research, 306, 575 (1998)]; and methods using  
N-acetylneuraminic acid synthetase, phosphoenolpyruvic acid  
and N-acetylmannosamine [Japanese Published Unexamined Patent  
Application No. 4961/98; Glycobiology, 7, 697 (1997)].

30 The above methods for producing N-acetylneuraminic acid  
require complicated operations or expensive materials such as  
pyruvic acid and phosphoenolpyruvic acid, and an economical  
method for producing N-acetylneuraminic acid has not been  
established yet.

35 So far, there has been no report describing or suggesting  
that N-acetylneuraminic acid can be produced by utilizing a

0045321-02500

culture of a microorganism or a treated matter thereof.

As for the N-acetylneuraminic acid aldolase, those derived from animals and plants are known, and it is known that microorganisms belonging to the genus Escherichia have the activity of this enzyme. Also known is the presence of the gene encoding this enzyme, nanA, in an Escherichia coli strain [Nucleic Acids Res., 13, 8843 (1985)].

N-Acetylneuraminic acid synthetase is known to be present in microorganisms belonging to the genera Escherichia, Neisseria and Streptococcus, etc., and it is known that an Escherichia coli strain has the gene encoding this enzyme, neuB [J. Bacteriol., 177, 312 (1995)].

N-Acetylglucosamine 2-epimerase is known to be present in pigs and rats. The properties of the enzyme derived from pig have been investigated [Biochemistry, 17, 3363 (1970)] and the gene encoding the enzyme [J. Biol. Chem., 271, 16294 (1996)] has been obtained. So far, no microorganism having the activity of this enzyme is known.

As to the production of pyruvic acid, a process for producing pyruvic acid by using a mutant of Escherichia coli is known [Biosci. Biotech. Biochem., 58, 2164 (1994)].

As to the production of phosphoenolpyruvic acid, a process for producing phosphoenolpyruvic acid by using microorganisms of Saccharomyces, etc. is known (Japanese Published Unexamined Patent Application No. 197778/94).

An object of the present invention is to provide a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. A further object of the present invention is to provide a process for producing N-acetylneuraminic acid without using expensive N-acetylmannosamine.

#### Summary of the Invention

The present inventors have made an intensive investigation to attain the above objects and have found that

N-acetylneuraminic acid can be efficiently produced from inexpensive materials by utilizing a microorganism which is capable of producing pyruvic acid or phosphoenolpyruvic acid. The present invention has been completed based on this finding.

5       The present invention relates to the following (1)-(11).

- (1) A process for producing N-acetylneuraminic acid which comprises:
  - allowing (i) a culture of a microorganism having N-acetylneuraminic acid aldolase activity or N-
  - 10       acetylneuraminic acid synthetase activity, or a treated matter of the culture, (ii) a culture of a microorganism capable of producing pyruvic acid or a treated matter of the culture when a microorganism having N-
  - 15       acetylneuraminic acid aldolase activity is used in (i) above, or a culture of a microorganism capable of producing phosphoenolpyruvic acid or a treated matter of the culture when a microorganism having N-acetylneuraminic acid synthetase activity is used in (i) above, (iii) N-
  - 20       acetylmannosamine, and (iv) an energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid to be present in an aqueous medium to form and accumulate N-acetylneuraminic acid in the aqueous medium; and
  - 25       recovering N-acetylneuraminic acid from the aqueous medium.
- (2) The process according to the above (1) wherein said N-acetylmannosamine is produced by allowing a culture of a microorganism having N-acetylglucosamine 2-epimerase activity or a treated matter of the culture and N-
- 30       acetylglucosamine to be present in an aqueous medium to form and accumulate N-acetylmannosamine in the aqueous medium.
- (3) The process according to the above (2) wherein said microorganism having N-acetylglucosamine 2-epimerase
- 35       activity carries a recombinant DNA composed of a DNA fragment comprising DNA encoding N-acetylglucosamine

00645321-002500

2-epimerase and a vector.

- (4) The process according to the above (3) wherein said DNA encoding N-acetylglucosamine 2-epimerase is DNA derived from a microorganism belonging to the genus Synechocystis.
- 5 (5) The process according to the above (3) or (4) wherein said DNA encoding N-acetylglucosamine 2-epimerase is selected from the group consisting of:
- (a) DNA encoding a protein having the amino acid sequence shown in SEQ ID NO: 1; and
- 10 (b) DNA having the nucleotide sequence shown in SEQ ID NO: 2.
- (6) The process according to any of the above (1)-(5) wherein said microorganism having N-acetylneuraminic acid aldolase activity is a microorganism belonging to the
- 15 genus Escherichia or Corynebacterium.
- (7) The process according to any of the above (1)-(6) wherein said microorganism having N-acetylneuraminic acid synthetase activity is a microorganism belonging to a
- 20 genus selected from the group consisting of Escherichia, Neisseria and Streptococcus.
- (8) The process according to any of the above (1)-(7) wherein said microorganism capable of producing pyruvic acid is a microorganism belonging to a genus selected from the
- 25 group consisting of Escherichia, Corynebacterium and Saccharomyces.
- (9) The process according to any of the above (1)-(8) wherein said microorganism capable of producing
- phosphoenolpyruvic acid is a microorganism belonging to a genus selected from the group consisting of Escherichia,
- 30 Corynebacterium and Saccharomyces.
- (10) The process according to any of the above (6)-(9) wherein said microorganism belonging to the genus Escherichia is Escherichia coli.
- (11) The process according to the above (6), (8) or (9) wherein
- 35 said microorganism belonging to the genus Corynebacterium is Corynebacterium ammoniagenes, Corynebacterium

09645321-082600



synthetase activity can be used in the process of the present invention. For example, microorganisms belonging to the genus Escherichia, Neisseria or Streptococcus may be used.

Examples of the microorganisms belonging to the genus  
5 Escherichia are those of the species Escherichia coli.

Also useful are transformants with N-acetylneuraminic acid synthetase activity enhanced by recombinant DNA techniques. Examples of such transformants include microorganisms carrying a recombinant DNA comprising neuB gene  
10 derived from Escherichia coli [J. Bacteriol., 177, 312 (1995)], specifically, Escherichia coli NM522/pYP18.

Any microorganism capable of producing pyruvic acid can be used in the process of the present invention. Examples of suitable microorganisms are those of the species Escherichia  
15 coli, Corynebacterium ammoniagenes, Corynebacterium glutamicum, Corynebacterium acetoacidophilum and Saccharomyces cerevisiae. Also useful are microorganisms with pyruvic acid productivity enhanced by mutagenesis or recombinant DNA techniques. For example, the Escherichia coli  
20 mutant described in Biosci. Biotech. Biochem., 58, 2164 (1994) can be used.

Any microorganism capable of producing phosphoenolpyruvic acid can be used in the process of the present invention. Examples of suitable microorganisms are  
25 those of the species Escherichia coli, Corynebacterium ammoniagenes, Corynebacterium glutamicum, Corynebacterium acetoacidophilum and Saccharomyces cerevisiae. An example of the microorganism of the species Saccharomyces cerevisiae is the strain described in Japanese Published Unexamined Patent  
30 Application No. 197778/94. Also useful are microorganisms with phosphoenolpyruvic acid productivity enhanced by mutagenesis or recombinant DNA techniques.

Any microorganism having N-acetylglucosamine 2-epimerase activity can be used in the process of the present  
35 invention. Suitable microorganisms include transformants with N-acetylglucosamine 2-epimerase activity enhanced by

00645321-082500

- recombinant DNA techniques. Specific examples of such transformants are Escherichia coli carrying the recombinant DNA pEPI1 comprising the N-acetylglucosamine 2-epimerase gene derived from pig (FERM BP-4602: U.S. Patent No. 5,795,767) and
- 5 Escherichia coli NM522/pYPl6 carrying a recombinant DNA comprising the N-acetylglucosamine 2-epimerase gene derived from a microorganism belonging to the genus Synechocystis.

- An example of the N-acetylglucosamine 2-epimerase gene derived from a microorganism belonging to the genus
- 10 Synechocystis is the gene encoding a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 which exists on the chromosome of Synechocystis sp. PCC6803, more specifically, the gene having the nucleotide sequence shown in SEQ ID NO: 2 (slr1975). The polypeptide having the amino acid sequence
- 15 shown in SEQ ID NO: 1 and the DNA having the nucleotide sequence shown in SEQ ID NO: 2 have been obtained for the first time by the present inventors according to the procedure described later in an example.

- A microorganism having N-acetylneuraminic acid aldolase
- 20 activity and the ability to produce pyruvic acid can be used alone for the production of N-acetylneuraminic acid from N-acetylmannosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be used in combination with a microorganism which can
- 25 complement such property for producing N-acetylneuraminic acid.

- N-Acetylmannosamine useful in the production of N-acetylneuraminic acid includes N-acetylmannosamine preparations (e.g., commercial products) and N-
- 30 acetylmannosamine prepared from N-acetylglucosamine by chemical reaction under alkaline conditions or by enzymatic conversion using N-acetylglucosamine 2-epimerase. Also useful are preparations containing N-acetylmannosamine formed and accumulated by allowing a culture of a microorganism having
- 35 N-acetylglucosamine 2-epimerase activity or a treated matter of the culture and N-acetylglucosamine to be present in an

aqueous medium, and N-acetylmannosamine purified from such preparations.

5 A microorganism having N-acetylneuraminic acid aldolase activity, N-acetylglucosamine 2-epimerase activity and the ability to produce pyruvic acid can be used alone for the production of N-acetylneuraminic acid from N-acetylglucosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be used in combination with a microorganism which can complement  
10 such property for producing N-acetylneuraminic acid.

N-Acetylglucosamine useful in the production of N-acetylneuraminic acid includes N-acetylglucosamine preparations (e.g., commercial products).

A microorganism having N-acetylneuraminic acid  
15 synthetase activity and the ability to produce phosphoenolpyruvic acid can also be used alone for the production of N-acetylneuraminic acid from N-acetylmannosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be  
20 used in combination with a microorganism which can complement such property for producing N-acetylneuraminic acid.

Further, a microorganism having N-acetylneuraminic acid synthetase activity, N-acetylglucosamine 2-epimerase activity and the ability to produce phosphoenolpyruvic acid  
25 can be used alone for the production of N-acetylneuraminic acid from N-acetylglucosamine. In cases where the microorganism employed is weak or lacking in any of the above properties, it may be used in combination with a microorganism which can complement such property for producing N-acetylneuraminic  
30 acid.

The microorganisms employed in the production of N-acetylneuraminic acid or N-acetylmannosamine may be subjected to reaction to form the product during their growth stage. Alternatively, after the completion of culturing of a  
35 microorganism, the resulting culture or a treated matter of the culture may be subjected to reaction.

00645321-082500



As described above, microorganisms prepared by using recombinant DNA techniques can be used in the production of N-acetylneuraminic acid or N-acetylmannosamine. Gene manipulating operations such as isolation and purification of plasmid DNA comprising a desired gene from a microorganism carrying the plasmid, cleavage of plasmid DNA with restriction enzymes, isolation and purification of cleaved DNA fragments, enzymatic ligation of DNA fragments, and transformation with recombinant DNA can be carried out according to known methods [e.g., Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989) (hereinafter referred to as Molecular Cloning, Second Edition); Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997) (hereinafter referred to as Current Protocols in Molecular Biology)]. Polymerase chain reaction (hereinafter referred to as PCR) can be carried out by a known method [PCR Protocols, Academic Press (1990)].

A gene concerned in the production of N-acetylneuraminic acid or N-acetylmannosamine can be expressed in a host by preparing a DNA fragment of an appropriate length containing the gene from a DNA fragment containing the gene by use of restriction enzymes or PCR, inserting the prepared DNA fragment into an appropriate expression vector at a site downstream of the promoter, and then introducing the expression vector comprising the above DNA into a host cell suited for the expression vector.

As the host cell, any bacterial cells, yeast cells, etc. which are capable of expressing a desired gene can be used.

The expression vectors that can be employed are those capable of autonomous replication or integration into chromosome in the above host cells and comprising a promoter at a position appropriate for the transcription of a desired DNA.

When a procaryotic cell such as a bacterial cell is used as the host cell, it is preferred that the expression vector for a gene is a recombinant DNA which is capable of autonomous

replication in the procaryotic cell and which comprises a promoter, a ribosome binding sequence, the desired DNA, and a transcription termination sequence. The vector may further comprise a gene regulating the promoter.

- 5 Examples of suitable expression vectors are pBTrp2 (Roche Diagnostics), pBTac1 (Roche Diagnostics), pBTac2 (Roche Diagnostics), pHelix1 (Roche Diagnostics), pKK233-2 (Amersham Pharmacia Biotech), pKK223-3 (Amersham Pharmacia Biotech), pGEX-2T (Amersham Pharmacia Biotech), pSE280 (Invitrogen), pGEMEX-1 (Promega), pQE-8 (QIAGEN), pQE-30 (QIAGEN), pET-3 (Novagen), pKYP10 (Japanese Published Unexamined Patent Application No. 110600/83), pKYP200 [Agric. Biol. Chem., 48, 669 (1984)], pLSA1 [Agric. Biol. Chem., 53, 277 (1989)], pGEL1 [Proc. Natl. Acad. Sci. USA, 82, 4306 (1985)],
- 10 pBluescript II SK+ (Stratagene), pBluescript II SK- (Stratagene), pTrs30 [prepared from Escherichia coli JM109/pTrs30 (FERM BP-5407)], pTrs32 [prepared from Escherichia coli JM109/pTrs32 (FERM BP-5408)], pUC19 [Gene, 33, 103 (1985)], pSTV28 (Takara Shuzo Co., Ltd.), pUC118 (Takara Shuzo Co., Ltd.), pPAC31 (WO 98/12343) and pPA1 (Japanese Published Unexamined Patent Application No. 233798/88).

- As the promoter, any promoters capable of functioning in host cells such as Escherichia coli can be used. For example,
- 25 promoters derived from Escherichia coli or phage, such as trp promoter (P<sub>trp</sub>), lac promoter (P<sub>lac</sub>), P<sub>L</sub> promoter, P<sub>R</sub> promoter and P<sub>SG</sub> promoter, SPO1 promoter, SPO2 promoter and penP promoter can be used. Artificially modified promoters such as a promoter in which two P<sub>trp</sub> are combined in tandem, lac promoter,
- 30 lacT7 promoter and letI promoter, etc. can also be used.

It is preferred to use a plasmid in which the distance between the Shine-Dalgarno sequence (ribosome binding sequence) and the initiation codon is adjusted to an appropriate length (e.g., 6-18 bases).

- 35 In the recombinant DNA of the present invention, the transcription termination sequence is not essential for the

expression of the desired DNA, but it is preferred that the transcription termination sequence lie immediately downstream of the structural gene.

- Examples of suitable procaryotes are microorganisms
- 5 belonging to the genera Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium and Pseudomonas, specifically, Escherichia coli XL1-Blue, Escherichia coli XL2-Blue, Escherichia coli DH1, Escherichia coli MC1000, Escherichia coli W1485, Escherichia coli NM522,
  - 10 Escherichia coli JM109, Escherichia coli HB101, Escherichia coli No. 49, Escherichia coli W3110, Escherichia coli NY49, Serratia ficaria, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Bacillus subtilis, Bacillus amyloliquefaciens, Brevibacterium immariophilum ATCC 14068,
  - 15 Brevibacterium saccharolyticum ATCC 14066, Corynebacterium ammoniagenes, Corynebacterium glutamicum ATCC 13032, Corynebacterium glutamicum ATCC 14067, Corynebacterium glutamicum ATCC 13869, Corynebacterium acetoacidophilum ATCC 13870, Microbacterium ammoniaphilum ATCC 15354 and
  - 20 Pseudomonas sp. D-0110.

- Introduction of the recombinant DNA can be carried out by any of the methods for introducing DNA into the above host cells, for example, the method using calcium ion [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], the protoplast method
- 25 (Japanese Published Unexamined Patent Application No. 248394/88) and electroporation [Nucleic Acids Research, 16, 6127 (1988)].

- When a yeast cell is used as the host cell, YEpl3 (ATCC 37115), YEpl24 (ATCC 37051), YCp50 (ATCC 37419), pHS19, pHS15,
- 30 etc. can be used as the expression vector.

- As the promoter, any promoters capable of functioning in yeast cells can be used. Suitable promoters include PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat shock polypeptide promoter,
- 35 MF  $\alpha$  1 promoter, CUP 1 promoter, etc.

Examples of suitable host cells are cells of yeast strains

00645321.082500

belonging to the genera Saccharomyces, Schizosaccharomyces, Kluyveromyces, Trichosporon, Schwanniomyces, Pichia and Candida, specifically, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis,  
5 Trichosporon pullulans, Schwanniomyces alluvius, Pichia pastoris and Candida utilis.

Introduction of the recombinant DNA can be carried out by any of the methods for introducing DNA into yeast cells, for example, electroporation [Methods in Enzymol., 194, 182  
10 (1990)], the spheroplast method [Proc. Natl. Acad. Sci. USA, 81, 4889 (1984)] and the lithium acetate method [J. Bacteriol., 153, 163 (1983)].

Culturing of the transformant of the present invention can be carried out by conventional methods for culturing the  
15 host cell of the transformant.

For the culturing of the transformant prepared by using a procaryotic cell such as Escherichia coli cell or a eucaryotic cell such as a yeast cell as the host cell, any of natural media and synthetic media can be used insofar as it is a medium  
20 suitable for efficient culturing of the transformant which contains carbon sources, nitrogen sources, inorganic substances, etc. which can be assimilated by the host used.

As the carbon sources, any carbon sources which can be assimilated by the host can be used. Examples of suitable  
25 carbon sources include carbohydrates such as glucose, fructose, sucrose, molasses containing them, starch and starch hydrolyzate; organic acids such as acetic acid and propionic acid; and alcohols such as ethanol and propanol.

As the nitrogen sources, ammonia, ammonium salts of  
30 inorganic or organic acids such as ammonium chloride, ammonium sulfate, ammonium acetate and ammonium phosphate, and other nitrogen-containing compounds can be used as well as peptone, meat extract, yeast extract, corn steep liquor, casein hydrolyzate, soybean cake, soybean cake hydrolyzate, and  
35 various fermented cells and digested products thereof.

Examples of the inorganic substances include potassium

dihydrogenphosphate, dipotassium hydrogenphosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate and calcium carbonate.

- 5       Culturing is usually carried out under aerobic conditions, for example, by shaking culture or submerged spinner culture under aeration, at 15-40°C for 5 hours to 7 days. The pH is maintained at 3.0-9.0 during the culturing. The pH adjustment is carried out by using an inorganic or organic acid, an alkali  
10       solution, urea, calcium carbonate, ammonia, etc.

      If necessary, antibiotics such as ampicillin and tetracycline may be added to the medium during the culturing.

- When a microorganism transformed with an expression vector comprising an inducible promoter is cultured, an  
15       inducer may be added to the medium, if necessary. For example, in the case of a microorganism transformed with an expression vector comprising lac promoter, isopropyl- $\beta$ -D-thiogalactopyranoside or the like may be added to the medium; and in the case of a microorganism transformed with an  
20       expression vector comprising trp promoter, indoleacrylic acid or the like may be added.

- The treated matters of a culture include concentrated culture, dried culture, cells obtained by centrifuging the culture, products obtained by treating the cells by various  
25       means such as drying, freeze-drying, treatment with a surfactant, ultrasonication, mechanical friction, treatment with a solvent, enzymatic treatment, protein fractionation and immobilization, an enzyme preparation obtained by extracting the cells, etc.

- 30       The amount of each microorganism used in the production of N-acetylneuraminic acid or N-acetylmannosamine is 1-500 g/l, preferably 1-300 g/l, as wet cells.

- As the energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid, any substance can  
35       be used that promotes the formation of pyruvic acid or phosphoenolpyruvic acid. Examples of preferred substances

are glucose and fructose. The substances may be used usually at a concentration of 10-300 g/l.

Aqueous media useful in the production of N-acetylneuraminic acid or N-acetylmannosamine include water, buffers such as phosphate buffer, carbonate buffer, acetate buffer, borate buffer, citrate buffer and Tris buffer, alcohols such as methanol and ethanol, esters such as ethyl acetate, ketones such as acetone, amides such as acetamide, etc. Also useful is a medium or culture broth of a microorganism used in the process for producing N-acetylneuraminic acid or N-acetylmannosamine.

If necessary, a chelating agent (e.g., phytic acid), a surfactant or an organic solvent may be added in the process for producing N-acetylneuraminic acid or N-acetylmannosamine.

Any surfactant that promotes the formation of N-acetylneuraminic acid or N-acetylmannosamine can be used. Suitable surfactants include nonionic surfactants such as polyoxyethylene octadecylamine (e.g., Nymeen S-215, NOF Corporation), cationic surfactants such as cetyltrimethylammonium bromide and alkyltrimethylbenzylammonium chloride (e.g., Cation F2-40E, NOF Corporation), anionic surfactants such as lauroyl sarcosinate, and tertiary amines such as alkyltrimethylamine (e.g., Tertiary Amine FB, NOF Corporation), which may be used alone or in combination. The surfactant is usually used at a concentration of 0.1-50 g/l.

As the organic solvent, xylene, toluene, aliphatic alcohols, acetone, ethyl acetate, etc. may be used usually at a concentration of 0.1-50 ml/l.

The reaction for forming N-acetylneuraminic acid or N-acetylmannosamine is carried out in an aqueous medium at pH 5-10, preferably pH 6-8, at 20-50°C for 1-96 hours.

Adenine, adenosine 5'-monotriphosphate (AMP), adenosine 5'-triphosphate (ATP), magnesium sulfate, magnesium chloride, etc. may be added for promoting the reaction. Adenine, AMP and ATP are usually used at a concentration of 0.01-100 mmol/l.

N-Acetylneuraminic acid or N-acetylmannosamine formed in the aqueous medium can be determined by using a carbohydrate analysis system (Dionex) or the like [Anal. Biochem., 189, 151 (1990)].

5 N-Acetylneuraminic acid or N-acetylmannosamine can be recovered from the reaction mixture by ordinary methods using active carbon, ion-exchange resins, etc.

Certain embodiments of the present invention are illustrated in the following examples. These examples are not  
10 to be construed as limiting the scope of the invention.

#### Example 1

Construction of a Strain Expressing N-Acetylneuraminic Acid Aldolase Gene Derived from Escherichia coli

15 Escherichia coli W3110 (ATCC 27325) was cultured by the method described in Current Protocols in Molecular Biology and the chromosomal DNA of the microorganism was isolated and purified.

The DNA primer shown in SEQ ID NO: 3 and the DNA primer shown in SEQ ID NO: 4 were synthesized by using a DNA synthesizer (Model 8905, PerSeptive Biosystems).

PCR was carried out using the above synthetic DNAs as primers and the chromosomal DNA of Escherichia coli W3110 (ATCC 27325) as a template. That is, PCR was carried out by 30 cycles,  
25 one cycle consisting of reaction at 94°C for one minute, reaction at 42°C for 2 minutes and reaction at 72°C for 3 minutes, using 40  $\mu$  l of a reaction mixture comprising 0.1  $\mu$  g of the chromosomal DNA, 0.5  $\mu$  mol/l each of the primers, 2.5 units of Pfu DNA polymerase (Stratagene), 4  $\mu$  l of buffer for Pfu  
30 DNA polymerase (10 x) (Stratagene) and 200  $\mu$  mol/l each of deoxyNTPs.

One-tenth of the resulting reaction mixture was subjected to agarose gel electrophoresis to confirm that the desired fragment was amplified. Then, the remaining reaction mixture  
35 was mixed with an equal amount of phenol/chloroform (1vol/1vol) saturated with TE [10 mmol/l Tris-HCl (pH 8.0),

0645321.082500

1 mmol/l EDTA], followed by centrifugation. The obtained upper layer was mixed with a two-fold volume of cold ethanol and allowed to stand at -80°C for 30 minutes. The resulting mixture was centrifuged to obtain a DNA precipitate.

- 5 The DNA precipitate was dissolved in 20  $\mu$  l of TE and 5  $\mu$  l of the solution was subjected to reaction to cleave the DNA with restriction enzymes HindIII and BamHI. DNA fragments were separated by agarose gel electrophoresis and a 1.2 kb fragment was recovered using Gene Clean II Kit (Bio 101).
- 10 pUC19 DNA [Gene, 33, 103 (1985)] (0.2  $\mu$  g) was cleaved with restriction enzymes HindIII and BamHI. DNA fragments were separated by agarose gel electrophoresis and a 2.7 kb fragment was recovered in the same manner.

- The 1.2 kb fragment and 2.7 kb fragment obtained above
- 15 were subjected to ligation reaction using a ligation kit at 16°C for 16 hours. Escherichia coli NM522 capable of producing pyruvic acid was transformed using the ligation mixture according to the known method described above, spread on LB agar medium containing 50  $\mu$  g/ml ampicillin, and cultured
- 20 overnight at 30°C.

- Escherichia coli NM522/pTA3, which is a transformant carrying the N-acetylneuraminic acid aldolase gene, nanA, was obtained from a colony of the transformant that grew on the above medium. A plasmid was extracted from this transformant
- 25 by a known method to obtain pTA3, which is a plasmid for expression of N-acetylneuraminic acid aldolase gene. The structure of this plasmid was confirmed by digestion with restriction enzymes (Fig. 1).

30 Example 2

Production of N-Acetylneuraminic Acid

- Escherichia coli NM522/pTA3 obtained in Example 1 was inoculated into 125 ml of LB medium containing 50  $\mu$  g/ml ampicillin in a 1-l Erlenmeyer flask with baffles, followed
- 35 by culturing at 28°C with stirring (220 r.p.m.) for 17 hours. The resulting culture (125 ml) was inoculated into 2.5 l of

09645321-082500



a liquid medium (pH unadjusted) comprising 10 g/l glucose, 12 g/l Bacto-tryptone (Difco Laboratories Inc.), 24 g/l yeast extract (Difco Laboratories Inc.), 2.3 g/l  $\text{KH}_2\text{PO}_4$ , 12.5 g/l  $\text{K}_2\text{HPO}_4$  and 50  $\mu$ g/ml ampicillin in a 5-l jar fermentor.

- 5 Culturing was carried out at 37°C for 6 hours under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 7.0 with 28% aqueous ammonia. Glucose was added, according to need, in the course of culturing. The resulting culture was
- 10 centrifuged to obtain wet cells. The wet cells could be stored at -20°C and could be used after thawing, according to need.

- A reaction mixture (30 ml) comprising 50 g/l Escherichia coli NM522/pTA3 wet cells, 65 g/l fructose, 40 g/l N-acetylmannosamine, 25 g/l  $\text{KH}_2\text{PO}_4$ , 5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml
- 15 beaker and subjected to reaction at 32°C for 25 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and  $\text{KH}_2\text{PO}_4$  were added
- 20 to the reaction mixture.

- After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 0.34 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

25

### Example 3

Construction of a Strain Expressing N-Acetylneuraminic acid synthetase Gene Derived from Escherichia coli

- Escherichia coli K235 (ATCC 13027) was cultured by the
- 30 method described in Current Protocols in Molecular Biology and the chromosomal DNA of the microorganism was isolated and purified.

- The DNA primer shown in SEQ ID NO: 5 and the DNA primer shown in SEQ ID NO: 6 were synthesized by using a DNA synthesizer
- 35 (Model 8905, PerSeptive Biosystems).

PCR was carried out using the above synthetic DNAs as

005280.1254960

primers and the chromosomal DNA of Escherichia coli K235 (ATCC 13027) as a template. That is, PCR was carried out by 30 cycles, one cycle consisting of reaction at 94°C for one minute, reaction at 42°C for 2 minutes and reaction at 72°C for 3 minutes, using 40  $\mu$  l of a reaction mixture comprising 0.1  $\mu$  g of the chromosomal DNA, 0.5  $\mu$  mol/l each of the primers, 2.5 units of Pfu DNA polymerase (Stratagene), 4  $\mu$  l of buffer for Pfu DNA polymerase (10 x) (Stratagene) and 200  $\mu$  mol/l each of deoxyNTPs.

One-tenth of the resulting reaction mixture was subjected to agarose gel electrophoresis to confirm that the desired fragment was amplified. Then, the remaining reaction mixture was mixed with an equal amount of phenol/chloroform (1vol/1vol) saturated with TE, followed by centrifugation. The obtained upper layer was mixed with a two-fold volume of cold ethanol and allowed to stand at -80°C for 30 minutes. The resulting mixture was centrifuged to obtain a DNA precipitate.

The DNA precipitate was dissolved in 20  $\mu$  l of TE and 5  $\mu$  l of the solution was subjected to reaction to cleave the DNA with restriction enzymes ClaI and BamHI. DNA fragments were separated by agarose gel electrophoresis and a 1.1 kb fragment was recovered using Gene Clean II Kit (Bio 101). pPAC31 DNA (WO98/12343) (0.2  $\mu$  g) was cleaved with restriction enzymes ClaI and BamHI. DNA fragments were separated by agarose gel electrophoresis and a 5.5 kb fragment was recovered in the same manner.

The 1.1 kb fragment and 5.5 kb fragment obtained above were subjected to ligation reaction using a ligation kit at 16°C for 16 hours. Escherichia coli NM522 capable of producing phosphoenolpyruvic acid was transformed using the ligation mixture according to the known method described above, spread on LB agar medium containing 50  $\mu$  g/ml ampicillin, and cultured overnight at 30°C.

Escherichia coli NM522/pYP18, which is a transformant carrying the N-acetylneuraminic acid synthetase gene, neuB, was obtained from a colony of the transformant that grew on

the above medium. A plasmid was extracted from this transformant by a known method to obtain pYP18, which is a plasmid for expression of N-acetylneuraminic acid synthetase gene. The structure of this plasmid was confirmed by digestion with restriction enzymes (Fig. 2).

#### Example 4

##### Production of N-Acetylneuraminic Acid

Escherichia coli NM522/pYP18 obtained in Example 3 was inoculated into 125 ml of LB medium containing 50  $\mu$ g/ml ampicillin in a 1-l Erlenmeyer flask with baffles, followed by culturing at 28°C with stirring (220 r.p.m.) for 17 hours. The resulting culture (125 ml) was inoculated into 2.5 l of a liquid medium (pH unadjusted) comprising 10 g/l glucose, 12 g/l Bacto-tryptone (Difco Laboratories Inc.), 24 g/l yeast extract (Difco Laboratories Inc.), 2.3 g/l  $\text{KH}_2\text{PO}_4$ , 12.5 g/l  $\text{K}_2\text{HPO}_4$  and 50  $\mu$ g/ml ampicillin in a 5-l jar fermentor. Culturing was carried out at 37°C for 4 hours and then at 40°C for 3 hours, under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 7.0 with 28% aqueous ammonia. Glucose was added, according to need, in the course of culturing.

The resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20°C and could be used after thawing, according to need.

A reaction mixture (30 ml) comprising 50 g/l Escherichia coli NM522/pYP18 wet cells, 65 g/l fructose, 40 g/l N-acetylmannosamine, 25 g/l  $\text{KH}_2\text{PO}_4$ , 5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32°C for 19 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and  $\text{KH}_2\text{PO}_4$  were added to the reaction mixture.

After the completion of reaction, the reaction product

09645371-082500

was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 1.4 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

##### 5 Example 5

##### Production of N-Acetylneuraminic Acid

Escherichia coli NM522/pYP18 obtained in Example 3 was cultured according to the method described in Example 2 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20°C and could be used after thawing, according to need.

Corynebacterium ammoniagenes ATCC 21170 was inoculated into 25 ml of a liquid medium comprising 50 g/l glucose, 10 g/l polypeptone (Nihon Pharmaceutical Industrial Co., Ltd.), 15 g/l yeast extract (Oriental Yeast Co., Ltd.), 5 g/l urea, 5 g/l  $(\text{NH}_4)_2\text{SO}_4$ , 1 g/l  $\text{KH}_2\text{PO}_4$ , 3 g/l  $\text{K}_2\text{HPO}_4$ , 1 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.1 g/l  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , 10 mg/l  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 10 mg/l  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ , 20 mg/l  $\text{MnSO}_4 \cdot 4\text{-}6\text{H}_2\text{O}$ , 20 mg/l L-cysteine, 10 mg/l calcium D-pantothenate, 5 mg/l vitamin  $\text{B}_1$ , 5 mg/l nicotinic acid and 30  $\mu$  g/l biotin (adjusted to pH 7.2 with 10 N NaOH) in a 300-ml Erlenmeyer flask with baffles, followed by culturing at 28°C with stirring (220 r.p.m.) for 24 hours.

The resulting culture (20 ml) was inoculated into 250 ml of a liquid medium having the same composition as above in a 25 2-l Erlenmeyer flask with baffles, followed by culturing at 28°C with stirring (220 r.p.m.) for 24 hours. The obtained culture was used as a seed culture.

The seed culture (250 ml) was inoculated into 2.25 l of a liquid medium comprising 150 g/l glucose, 5 g/l meat extract (Kyokuto Pharmaceutical Ind. Co., Ltd.), 10 g/l  $\text{KH}_2\text{PO}_4$ , 10 g/l  $\text{K}_2\text{HPO}_4$ , 10 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 0.1 g/l  $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ , 20 mg/l  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ , 10 mg/l  $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ , 20 mg/l  $\text{MnSO}_4 \cdot 4\text{-}6\text{H}_2\text{O}$  (separately sterilized), 15 mg/l  $\beta$ -alanine (separately sterilized), 20 mg/l L-cysteine, 100  $\mu$  g/l biotin, 2 g/l urea and 5 mg/l vitamin  $\text{B}_1$  (separately sterilized) (adjusted to pH 7.2 with 10 N NaOH) in a 5-l jar fermentor. Culturing was carried out at 32°C for

24 hours under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 6.8 with 28% aqueous ammonia.

- The resulting culture was centrifuged to obtain wet cells.  
 5 The wet cells could be stored at -20° C and could be used after thawing, according to need.

- A reaction mixture (30 ml) comprising 50 g/l Escherichia coli NM522/pYP18 wet cells, 150 g/l Corynebacterium ammoniagenes ATCC 21170 wet cells, 65 g/l fructose, 40 g/l  
 10 N-acetylmannosamine, 25 g/l  $\text{KH}_2\text{PO}_4$ , 5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32° C for 6 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2  
 15 with 4 N NaOH, and according to need, fructose and  $\text{KH}_2\text{PO}_4$  were added to the reaction mixture.

- After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 3.1 g/l N-acetylneuraminic acid  
 20 was formed and accumulated in the reaction mixture.

#### Example 6

Construction of a Strain Expressing N-Acetylglucosamine 2-Epimerase Gene Derived from Synechocystis

- 25 Blast Search of Genbank and a similarity search on CyanoBase (<http://www.kazusa.or.jp/cyano/>), which is a database of the genomic sequence of Synechocystis sp. (PCC6803), were conducted with the amino acid sequence of N-acetylglucosamine 2-epimerase derived from pig [J. Biol.  
 30 Chem., 271, 16294 (1996)] as a query. As a result, the above amino acid sequence showed a high homology to the sequence derived from Synechocystis sp. (PCC6803) described as a renin-binding protein (slr1975).

- Synechocystis sp. (PCC6803) was cultured by the method  
 35 described in J. Gen. Microbiol., 111, 1 (1979), and the chromosomal DNA of the microorganism was isolated and purified

by the method described in Current Protocols in Molecular Biology.

PCR was carried out according to the method described in Example 1 using the DNAs shown in SEQ ID NOS: 7 and 8 which had been synthesized by using a DNA synthesizer (Model 8905, PerSeptive Biosystems) as primers and the chromosomal DNA of Synechocystis sp. (PCC6803) as a template.

One-tenth of the resulting reaction mixture was subjected to agarose gel electrophoresis to confirm that the desired fragment was amplified. Then, the remaining reaction mixture was mixed with an equal amount of phenol/chloroform (1vol/1vol) saturated with TE.

The resulting mixture was centrifuged and the obtained upper layer was mixed with a two-fold volume of cold ethanol and allowed to stand at -80°C for 30 minutes. The resulting mixture was centrifuged to obtain a DNA precipitate.

The DNA precipitate was dissolved in 20  $\mu$  l of TE and 5  $\mu$  l of the solution was subjected to reaction to cleave the DNA with restriction enzymes ClaI and BamHI. DNA fragments were separated by agarose gel electrophoresis and a 1.2 kb fragment was recovered using Gene Clean II Kit (Bio 101).

pPAC31 DNA (0.2  $\mu$  g) was cleaved with restriction enzymes ClaI and BamHI. DNA fragments were separated by agarose gel electrophoresis and a 5.5 kb fragment was recovered in the same manner.

The 1.2 kb fragment and 5.5 kb fragment obtained above were subjected to ligation reaction using a ligation kit at 16°C for 16 hours.

Escherichia coli NM522 was transformed using the ligation mixture according to the known method described above, spread on LB agar medium containing 50  $\mu$  g/ml ampicillin, and cultured overnight at 30°C.

Escherichia coli NM522/pYP16, which is a transformant carrying the DNA encoding N-acetylglucosamine 2-epimerase derived from Synechocystis sp., was obtained from a colony of the transformant that grew on the above medium. A plasmid was

extracted from this transformant by a known method to obtain expression plasmid pYP16. The structure of this plasmid was confirmed by digestion with restriction enzymes (Fig. 3).

5 Example 7

Production of N-Acetylneuraminic Acid

Escherichia coli NM522/pTA3 obtained in Example 1 was cultured according to the method described in Example 2 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20°C and could be used after thawing, according to need.

Escherichia coli NM522/pYP16 obtained in Example 6 was inoculated into 125 ml of LB medium containing 50  $\mu$  g/ml ampicillin in a 1-l Erlenmeyer flask with baffles, followed by culturing at 28°C with stirring (220 r.p.m.) for 17 hours. The resulting culture (125 ml) was inoculated into 2.5 l of a liquid medium (pH unadjusted) comprising 10 g/l glucose, 12 g/l Bacto-tryptone (Difco Laboratories Inc.), 24 g/l yeast extract (Difco Laboratories Inc.), 2.3 g/l  $\text{KH}_2\text{PO}_4$ , 12.5 g/l  $\text{K}_2\text{HPO}_4$  and 50  $\mu$  g/ml ampicillin in a 5-l jar fermentor. Culturing was carried out at 30°C for 4 hours and then at 40°C for 3 hours, under the conditions of stirring at 600 r.p.m. and aeration at 2.5 l/min. During the culturing, the pH of culture was maintained at 7.0 with 28% aqueous ammonia. Glucose was added, according to need, in the course of culturing.

The resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20°C and could be used after thawing, according to need.

Corynebacterium ammoniagenes ATCC 21170 was cultured according to the method described in Example 5 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at -20°C and could be used after thawing, according to need.

A reaction mixture (30 ml) comprising 50 g/l Escherichia coli NM522/pTA3 wet cells, 50 g/l Escherichia coli NM522/pYP16

005220-1225796

wet cells, 150 g/l Corynebacterium ammoniagenes ATCC 21170 wet cells, 65 g/l fructose, 180 g/l N-acetylglucosamine, 25 g/l  $\text{KH}_2\text{PO}_4$ , 5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32°C for 24 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and  $\text{KH}_2\text{PO}_4$  were added to the reaction mixture.

After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 1.0 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

#### Example 8

Production of N-Acetylneuraminic Acid

Escherichia coli NM522/pYP18 obtained in Example 3 and Escherichia coli NM522/pYP16 obtained in Example 6 were cultured according to the methods described in Examples 4 and 7, respectively, and the resulting cultures were centrifuged to obtain wet cells. The wet cells could be stored at -20°C and could be used after thawing, according to need.

A reaction mixture (30 ml) comprising 50 g/l Escherichia coli NM522/pYP16 wet cells, 50 g/l Escherichia coli NM522/pYP18 wet cells, 65 g/l fructose, 180 g/l N-acetylglucosamine, 25 g/l  $\text{KH}_2\text{PO}_4$ , 5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction at 32°C for 11 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, fructose and  $\text{KH}_2\text{PO}_4$  were added to the reaction mixture.

After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 1.3 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.



Example 9

## Production of N-Acetylneuraminic Acid

- 5 Escherichia coli NM522/pYP18 obtained in Example 3 and  
cultured according to the methods described in Examples 4 and  
7, respectively, and the resulting cultures were centrifuged  
to obtain wet cells. The wet cells could be stored at -20°C  
and could be used after thawing, according to need.
- 10 Corynebacterium ammoniagenes ATCC 21170 was cultured  
according to the method described in Example 5 and the resulting  
culture was centrifuged to obtain wet cells. The wet cells  
could be stored at -20°C and could be used after thawing,  
according to need.
- 15 A reaction mixture (30 ml) comprising 50 g/l Escherichia  
coli NM522/pYP16 wet cells, 50 g/l Escherichia coli  
NM522/pYP18 wet cells, 150 g/l Corynebacterium ammoniagenes  
ATCC 21170 wet cells, 65 g/l fructose, 180 g/l N-  
acetylglucosamine, 25 g/l  $\text{KH}_2\text{PO}_4$ , 5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 5 g/l phytic  
20 acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml  
beaker and subjected to reaction at 32°C for 24 hours with  
stirring (900 r.p.m.) using a magnetic stirrer. During the  
reaction, the pH of reaction mixture was maintained at 7.2 with  
4 N NaOH, and according to need, fructose and  $\text{KH}_2\text{PO}_4$  were added  
25 to the reaction mixture.

After the completion of reaction, the reaction product  
was analyzed by using a carbohydrate analysis system (DX-500,  
Dionex) and it was found that 4.3 g/l N-acetylneuraminic acid  
was formed and accumulated in the reaction mixture.

30

Example 10

## Production of N-Acetylneuraminic Acid

- 35 Escherichia coli NM522/pYP18 obtained in Example 3 and  
Escherichia coli NM522/pYP16 obtained in Example 6 were  
cultured according to the methods described in Examples 4 and  
7, respectively, and the resulting cultures were centrifuged

05645321.02500

to obtain wet cells. The wet cells could be stored at  $-20^{\circ}\text{C}$  and could be used after thawing, according to need.

- 5 Corynebacterium ammoniagenes ATCC 21170 was cultured according to the method described in Example 5 and the resulting culture was centrifuged to obtain wet cells. The wet cells could be stored at  $-20^{\circ}\text{C}$  and could be used after thawing, according to need.

- 10 A reaction mixture (30 ml) comprising 50 g/l Escherichia coli NM522/pYP16 wet cells, 50 g/l Escherichia coli NM522/pYP18 wet cells, 150 g/l Corynebacterium ammoniagenes ATCC 21170 wet cells, 100 g/l glucose, 180 g/l N-acetylglucosamine, 5 g/l adenine, 15 g/l  $\text{KH}_2\text{PO}_4$ , 5 g/l  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ , 5 g/l phytic acid, 4 g/l Nymeen S-215 and 10 ml/l xylene was put into a 200-ml beaker and subjected to reaction
- 15 at  $32^{\circ}\text{C}$  for 22 hours with stirring (900 r.p.m.) using a magnetic stirrer. During the reaction, the pH of reaction mixture was maintained at 7.2 with 4 N NaOH, and according to need, glucose and  $\text{KH}_2\text{PO}_4$  were added to the reaction mixture.

- 20 After the completion of reaction, the reaction product was analyzed by using a carbohydrate analysis system (DX-500, Dionex) and it was found that 12.3 g/l N-acetylneuraminic acid was formed and accumulated in the reaction mixture.

## SEQUENCE LISTING

- 5 <110> Satoshi KOIZUMI  
 Kazuhiko TABATA  
 Tetsuo ENDO  
 Akio OZAKI
- 10 <120> Process for producing N-acetylneuraminic acid
- 10 <130> 11229
- 15 <150> H11-242670  
 <151> 1999-08-30
- 15 <160> 8
- <170> PatentIn Ver. 2.0
- 20 <210> 1  
 <211> 391  
 <212> PRT  
 <213> Synechocystis sp. (PCC6803)
- 25 <400> 1  
 Met Ile Ala His Arg Arg Gln Glu Leu Ala Gln Gln Tyr Tyr Gln Ala  
 1 5 10 15  
 Leu His Gln Asp Val Leu Pro Phe Trp Glu Lys Tyr Ser Leu Asp Arg  
 20 25 30  
 Gln Gly Gly Gly Tyr Phe Thr Cys Leu Asp Arg Lys Gly Gln Val Phe  
 35 40 45  
 Asp Thr Asp Lys Phe Ile Trp Leu Gln Asn Arg Gln Val Trp Gln Phe  
 50 55 60

002280.1225490

Ala Val Phe Tyr Asn Arg Leu Glu Pro Lys Pro Gln Trp Leu Glu Ile  
65 70 75 80

Ala Arg His Gly Ala Asp Phe Leu Ala Arg His Gly Arg Asp Gln Asp  
5 85 90 95

Gly Asn Trp Tyr Phe Ala Leu Asp Gln Glu Gly Lys Pro Leu Arg Gln  
100 105 110

Pro Tyr Asn Val Phe Ser Asp Cys Phe Ala Ala Met Ala Phe Ser Gln  
10 115 120 125

Tyr Ala Leu Ala Ser Gly Ala Gln Glu Ala Lys Ala Ile Ala Leu Gln  
130 135 140

Ala Tyr Asn Asn Val Leu Arg Arg Gln His Asn Pro Lys Gly Gln Tyr  
145 150 155 160

Glu Lys Ser Tyr Pro Gly Thr Arg Pro Leu Lys Ser Leu Ala Val Pro  
20 165 170 175

Met Ile Leu Ala Asn Leu Thr Leu Glu Met Glu Trp Leu Leu Pro Pro  
180 185 190

Thr Thr Val Glu Glu Val Leu Ala Gln Thr Val Arg Glu Val Met Thr  
25 195 200 205

Asp Phe Leu Asp Pro Glu Ile Gly Leu Met Arg Glu Ala Val Thr Pro  
210 215 220

Thr Gly Glu Phe Val Asp Ser Phe Glu Gly Arg Leu Leu Asn Pro Gly  
30 225 230 235 240

His Gly Ile Glu Ala Met Trp Phe Met Met Asp Ile Ala Gln Arg Ser  
35 245 250 255

000220-1254960

	Gly Asp Arg Gln Leu Gln Glu Gln Ala Ile Ala Val Val Leu Asn Thr	
	260	265 270
5	Leu Glu Tyr Ala Trp Asp Glu Glu Phe Gly Gly Ile Phe Tyr Phe Leu	
	275	280 285
	Asp Arg Gln Gly His Pro Pro Gln Gln Leu Glu Trp Asp Gln Lys Leu	
	290	295 300
10	Trp Trp Val His Leu Glu Thr Leu Val Ala Leu Ala Lys Gly His Gln	
	305	310 315 320
	Ala Thr Gly Gln Glu Lys Cys Trp Gln Trp Phe Glu Arg Val His Asp	
15	325	330 335
	Tyr Ala Trp Ser His Phe Ala Asp Pro Glu Tyr Gly Glu Trp Phe Gly	
	340	345 350
20	Tyr Leu Asn Arg Arg Gly Glu Val Leu Leu Asn Leu Lys Gly Gly Lys	
	355	360 365
	Trp Lys Gly Cys Phe His Val Pro Arg Ala Leu Trp Leu Cys Ala Glu	
	370	375 380
25	Thr Leu Gln Leu Pro Val Ser	
	385	390
	<210> 2	
30	<211> 1173	
	<212> DNA	
	<213> Synechocystis sp. (PCC6803)	
	<400> 2	
35	atg att gcc cat cgc cgt cag gag tta gcc cag caa tat tac cag gct	48
	Met Ile Ala His Arg Arg Gln Glu Leu Ala Gln Gln Tyr Tyr Gln Ala	

00545321.082500

	1	5	10	15	
	tta cac cag gac gla ttg ccc ttt tgg gaa aaa tat tcc ctg gat cgc	96			
	Leu His Gln Asp Val Leu Pro Phe Trp Glu Lys Tyr Ser Leu Asp Arg				
5	20	25	30		
	cag ggg ggc ggt tac ttt acc tgc tta gac cgt aaa ggc cag gtt ttt	144			
	Gln Gly Gly Gly Tyr Phe Thr Cys Leu Asp Arg Lys Gly Gln Val Phe				
	35	40	45		
10					
	gac aca gat aaa ttc att tgg tta caa aac cgt cag gla tgg cag ttt	192			
	Asp Thr Asp Lys Phe Ile Trp Leu Gln Asn Arg Gln Val Trp Gln Phe				
	50	55	60		
15					
	gcc gtt ttc tac aac cgt ttg gaa cca aaa ccc caa tgg tta gaa att	240			
	Ala Val Phe Tyr Asn Arg Leu Glu Pro Lys Pro Gln Trp Leu Glu Ile				
	65	70	75	80	
	gcc cgc cat ggt gct gat ttt tta gct cgc cac ggc cga gat caa gac	288			
20					
	Ala Arg His Gly Ala Asp Phe Leu Ala Arg His Gly Arg Asp Gln Asp				
	85	90	95		
	ggt aat tgg tat ttt gct ttg gat cag gaa ggc aaa ccc ctg cgt caa	336			
	Gly Asn Trp Tyr Phe Ala Leu Asp Gln Glu Gly Lys Pro Leu Arg Gln				
25	100	105	110		
	ccc tat aac gtt ttt tcc gat tgc ttc gcc gcc atg gcc ttt agt caa	384			
	Pro Tyr Asn Val Phe Ser Asp Cys Phe Ala Ala Met Ala Phe Ser Gln				
	115	120	125		
30					
	tat gcc tta gcc agt ggg gcg cag gaa gct aaa gcc att gcc ctg cag	432			
	Tyr Ala Leu Ala Ser Gly Ala Gln Glu Ala Lys Ala Ile Ala Leu Gln				
	130	135	140		
35					
	gcc tac aat aac gtc cta cgc cgt cag cac aat ccc aaa ggt caa tac	480			
	Ala Tyr Asn Asn Val Leu Arg Arg Gln His Asn Pro Lys Gly Gln Tyr				

00645321.082500

	145				150					155					160		
	gag	aag	tcc	tat	cca	ggt	act	aga	ccc	ctc	aaa	tcc	ctg	gcg	gtg	ccg	528
	Glu	Lys	Ser	Tyr	Pro	Gly	Thr	Arg	Pro	Leu	Lys	Ser	Leu	Ala	Val	Pro	
5					165					170					175		
	atg	att	tta	gcc	aac	ctc	acc	ctg	gag	atg	gaa	tgg	tta	tta	ccg	cc	576
	Met	Ile	Leu	Ala	Asn	Leu	Thr	Leu	Glu	Met	Glu	Trp	Leu	Leu	Pro	Pro	
				180					185					190			
10																	
	act	acc	gtg	gaa	gag	gtg	tig	gcc	caa	acc	gtc	aga	gaa	gtg	atg	acg	624
	Thr	Thr	Val	Glu	Glu	Val	Leu	Ala	Gln	Thr	Val	Arg	Glu	Val	Met	Thr	
				195				200					205				
15																	
	gat	ttc	ctc	gac	cca	gaa	ata	gga	tta	atg	cgg	gaa	gcg	gig	acc	ccc	672
	Asp	Phe	Leu	Asp	Pro	Glu	Ile	Gly	Leu	Met	Arg	Glu	Ala	Val	Thr	Pro	
		210					215					220					
20																	
	aca	gga	gaa	ttt	gtt	gat	agt	ttt	gaa	ggg	cgg	tig	ctc	aac	cca	gga	720
	Thr	Gly	Glu	Phe	Val	Asp	Ser	Phe	Glu	Gly	Arg	Leu	Leu	Asn	Pro	Gly	
		225					230				235				240		
25																	
	cac	ggc	att	gaa	gcc	atg	tgg	ttc	atg	atg	gac	att	gcc	caa	cgc	tcc	768
	His	Gly	Ile	Glu	Ala	Met	Trp	Phe	Met	Met	Asp	Ile	Ala	Gln	Arg	Ser	
				245						250					255		
30																	
	ggc	gat	cgc	cag	tta	cag	gag	caa	gcc	att	gca	gtg	gtg	tig	aac	acc	816
	Gly	Asp	Arg	Gln	Leu	Gln	Glu	Gln	Ala	Ile	Ala	Val	Val	Leu	Asn	Thr	
				260				265						270			
35																	
	ctg	gaa	tat	gcc	tgg	gat	gaa	gaa	ttt	ggt	ggc	ata	ttt	tat	ttc	ctt	864
	Leu	Glu	Tyr	Ala	Trp	Asp	Glu	Glu	Phe	Gly	Gly	Ile	Phe	Tyr	Phe	Leu	
				275				280					285				
40																	
	gat	cgc	cag	ggc	cac	cc	ccc	caa	caa	ctg	gaa	tgg	gac	caa	aag	ctc	912
	Asp	Arg	Gln	Gly	His	Pro	Pro	Gln	Gln	Leu	Glu	Trp	Asp	Gln	Lys	Leu	

	290	295	300	
	tgg tgg gta cat ttg gaa acc ctg gtt gcc cta gcc aag ggc cac caa			960
	Trp Trp Val His Leu Glu Thr Leu Val Ala Leu Ala Lys Gly His Gln			
5	305	310	315	320
	gcc act ggc caa gaa aaa tgt tgg caa tgg ttt gag cgg gtc cat gat			1008
	Ala Thr Gly Gln Glu Lys Cys Trp Gln Trp Phe Glu Arg Val His Asp			
	325	330	335	
10				
	tac gcc tgg agt cat ttc gcc gat cct gag tat ggg gaa tgg ttt ggc			1056
	Tyr Ala Trp Ser His Phe Ala Asp Pro Glu Tyr Gly Glu Trp Phe Gly			
	340	345	350	
15				
	tac ctg aat cgc cgg gga gag gtg tta ctc aac cta aaa ggg ggg aaa			1104
	Tyr Leu Asn Arg Arg Gly Glu Val Leu Leu Asn Leu Lys Gly Gly Lys			
	355	360	365	
	tgg aaa ggg tgc ttc cac gig ccc cga gct ctg tgg ctc tgt gcg gaa			1152
20	Trp Lys Gly Cys Phe His Val Pro Arg Ala Leu Trp Leu Cys Ala Glu			
	370	375	380	
	act ctc caa ctt ccg gtt agt			1173
	Thr Leu Gln Leu Pro Val Ser			
25	385	390		
	<210> 3			
	<211> 24			
30	<212> DNA			
	<213> Artificial Sequence			
	<220>			
	<223> Synthetic DNA			
35				
	<400> 3			

005280.1254596



gtgtaagctt tctgtatggg gtgt

24

 $5 \quad \langle 210 \rangle \quad 4$ 

&lt;211&gt; 26

&lt;212&gt; DNA

### ⟨213⟩ Artificial Sequence

10  $\langle 220 \rangle$ 

### ⟨223⟩ Synthetic DNA

$\langle 400 \rangle$  4

gcagggaicc caaccaggca gcggaa

15 26

&lt;210&gt; 5

&lt;211&gt; 32

20 &lt;212&gt; DNA

### ⟨213⟩ Artificial Sequence

 $\langle 220 \rangle$ 

## 〈223〉 Synthetic DNA

25

<400> 5

tttaicgata ttaattaggg ggaatgaatg ag

32

30

$\langle 210 \rangle$  6

&lt;211&gt; 33

&lt;212&gt; DNA

### 〈213〉 Artificial Sequence

35

 $\langle 220 \rangle$

<223> Synthetic DNA

<400> 6

tttggatcct cattatccccc cctgatTTTT gaa

5 33

<210> 7

<211> 36

10 <212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic DNA

15

<400> 7

taaalcgata ttgtgaatg atgcccacgc cgtcag

36

20 <210> 8

<211> 36

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Synthetic DNA

<400> 8

aaaggatcct taactaacgc gaagttggag agtttc

36

000000-1234567890

What is claimed is:

1. A process for producing N-acetylneuraminic acid which comprises:

- 5 allowing (i) a culture of a microorganism having N-acetylneuraminic acid aldolase activity or N-acetylneuraminic acid synthetase activity, or a treated matter of the culture, (ii) a culture of a microorganism capable of producing pyruvic acid or a treated matter of the culture when a microorganism  
10 having N-acetylneuraminic acid aldolase activity is used in (i) above, or a culture of a microorganism capable of producing phosphoenolpyruvic acid or a treated matter of the culture when a microorganism having N-acetylneuraminic acid synthetase activity is used in (i) above, (iii) N-acetylmannosamine, and  
15 (iv) an energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid to be present in an aqueous medium to form and accumulate N-acetylneuraminic acid in the aqueous medium; and  
recovering N-acetylneuraminic acid from the aqueous medium.

20

2. The process according to claim 1, wherein said N-acetylmannosamine is produced by allowing a culture of a microorganism having N-acetylglucosamine 2-epimerase activity or a treated matter of the culture and N-  
25 acetylglucosamine to be present in an aqueous medium to form and accumulate N-acetylmannosamine in the aqueous medium.

3. The process according to claim 2, wherein said microorganism having N-acetylglucosamine 2-epimerase  
30 activity carries a recombinant DNA composed of a DNA fragment comprising DNA encoding N-acetylglucosamine 2-epimerase and a vector.

4. The process according to claim 3, wherein said DNA  
35 encoding N-acetylglucosamine 2-epimerase is DNA derived from a microorganism belonging to the genus Synechocystis.

00645321-002500

5. The process according to claim 3 or 4, wherein said DNA encoding N-acetylglucosamine 2-epimerase is selected from the group consisting of:

- 5 (a) DNA encoding a protein having the amino acid sequence shown in SEQ ID NO: 1; and  
(b) DNA having the nucleotide sequence shown in SEQ ID NO: 2.

6. The process according to any of claims 1-5, wherein  
10 said microorganism having N-acetylneuraminic acid aldolase activity is a microorganism belonging to the genus Escherichia or Corynebacterium.

7. The process according to any of claims 1-6, wherein  
15 said microorganism having N-acetylneuraminic acid synthetase activity is a microorganism belonging to a genus selected from the group consisting of Escherichia, Neisseria and Streptococcus.

8. The process according to any of claims 1-7, wherein  
20 said microorganism capable of producing pyruvic acid is a microorganism belonging to a genus selected from the group consisting of Escherichia, Corynebacterium and Saccharomyces.

9. The process according to any of claims 1-8, wherein  
25 said microorganism capable of producing phosphoenolpyruvic acid is a microorganism belonging to a genus selected from the group consisting of Escherichia, Corynebacterium and Saccharomyces.

10. The process according to any of claims 6-9, wherein  
30 said microorganism belonging to the genus Escherichia is Escherichia coli.

11. The process according to claim 6, 8 or 9, wherein said  
35 microorganism belonging to the genus Corynebacterium is

0045321-082500

Corynebacterium ammoniagenes, Corynebacterium glutamicum or  
Corynebacterium acetoacidophilum.


005280.1235496

## ABSTRACT OF THE DISCLOSURE

The present invention provides a process for economically producing N-acetylneuraminic acid without using expensive materials such as pyruvic acid and phosphoenolpyruvic acid. The process comprises: allowing (i) a culture of a microorganism having N-acetylneuraminic acid aldolase activity or N-acetylneuraminic acid synthetase activity, or a treated matter of the culture, (ii) a culture of a microorganism capable of producing pyruvic acid or a treated matter of the culture, or a culture of a microorganism capable of producing phosphoenolpyruvic acid or a treated matter of the culture, (iii) N-acetylmannosamine, and (iv) an energy source which is necessary for the formation of pyruvic acid or phosphoenolpyruvic acid to be present in an aqueous medium to form and accumulate N-acetylneuraminic acid in the aqueous medium; and recovering N-acetylneuraminic acid from the aqueous medium.


004521.032500

Fig. 1



005280.1254960  
00645321.082500


Fig. 2



09645321.082500



Fig. 3



005280-1254960

COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION  
(Page 1)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled \_\_\_\_\_

PROCESS FOR PRODUCING N-ACETYLNEURAMINIC ACID

the specification of which ☒ is attached hereto ☐ was filed on \_\_\_\_\_ as United States Application No. or PCT International Application No. \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b), of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designates at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed:

Country	Application No.	Filed (Day/Mo./Yr.)	(Yes/No) Priority Claimed
Japan	242670/99	30 August 1999	Yes

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Application No.	Filed (Day/Mo./Yr.)	Status (Patented, Pending, Abandoned)
-----------------	---------------------	---------------------------------------

I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number:

FITZPATRICK, CELLA, HARPER & SCINTO  
Customer Number: 05514

00645321-0005514

COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION  
(Page 2)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or First Inventor Satoshi Koizumi  
Inventor's Signature Satoshi Koizumi  
Date August 21, 2000 Citizen/Subject of JAPAN  
Residence Tokyo, Japan  
Post Office Address c/o Tokyo Research Laboratories, KYOWA HAKKO KOGYO CO., LTD., 6-6, Asahi-machi 3-chome, Machida-shi, Tokyo 194-8533 Japan

Full Name of Second Joint Inventor, if any Kazuhiko Tabata  
Inventor's Signature Kazuhiko Tabata  
Date August 18, 2000 Citizen/Subject of JAPAN  
Residence Hofu-shi, Japan  
Post Office Address c/o Technical Research Laboratories, KYOWA HAKKO KOGYO CO., LTD., 1-1, Kyowa-cho, Hofu-shi, Yamaguchi 747-8522 Japan

Full Name of Third Joint Inventor, if any Tetsuo Endo  
Inventor's Signature Tetsuo Endo  
Date August 21, 2000 Citizen/Subject of JAPAN  
Residence Tokyo, Japan  
Post Office Address c/o Tokyo Research Laboratories, KYOWA HAKKO KOGYO CO., LTD., 6-6, Asahi-machi 3-chome, Machida-shi, Tokyo 194-8533 Japan

Full Name of Fourth Joint Inventor, if any Shiro Ozaki  
Inventor's Signature Shiro Ozaki  
Date August 18, 2000 Citizen/Subject of JAPAN  
Residence Tokyo, Japan  
Post Office Address c/o Technical Research Laboratories, KYOWA HAKKO KOGYO CO., LTD., 1-1, Kyowa-cho, Hofu-shi, Yamaguchi 747-8522 Japan

09645321-085000

5.1183

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
SATOSHI KOIZUMI, ET AL. ) : Examiner: Not Yet Assigned  
Application No.: N/Y/A ) : Group Art Unit: N/Y/A  
Filed: Currently herewith ) :  
For: PROCESS FOR PRODUCING ) :  
N-ACETYLNEURAMINIC ACID : August 24, 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231


SUBMISSION OF COMPUTER READABLE FORM  
UNDER 37 C.F.R. § 1.821(e)

Sir:

Applicants submit herewith a computer readable form under 37 C.F.R. § 1.821(e). The content of the computer readable form and the Sequence Listing filed herewith are the same.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

  
\_\_\_\_\_  
Attorney for Applicants  
Lawrence S. Perry  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

**DESIGNER** **RENTALS** **INC.**

<120> Process for producing N-acetylneuraminic acid

&lt;150&gt; H11-242670

<160> 8

 $\langle 210 \rangle$  1

<211> 391

<212> PRT

<213> *Synechocystis* sp. (PCC6803)

 $\langle 400 \rangle$  1

Met Ile Ala His Arg Arg Gln Glu Leu Ala Gln Gln Tyr Tyr Gln Ala  
1 5 10 15

Leu His Gln Asp Val Leu Pro Phe Trp Glu Lys Tyr Ser Leu Asp Arg  
20 25 30

Gln Gly Gly Gly Tyr Phe Thr Cys Leu Asp Arg Lys Gly Gln Val Phe  
35 40 45

Asp Thr Asp Lys Phe Ile Trp Leu Gln Asn Arg Gln Val Trp Gln Phe  
50 55 60

Ala Val Phe Tyr Asn Arg Leu Glu Pro Lys Pro Gln Trp Leu Glu Ile  
65 70 75 80

Ala Arg His Gly Ala Asp Phe Leu Ala Arg His Gly Arg Asp Gln Asp  
85 90 95

Gly Asn Trp Tyr Phe Ala Leu Asp Gln Glu Gly Lys Pro Leu Arg Gln  
100 105 110

Pro Tyr Asn Val Phe Ser Asp Cys Phe Ala Ala Met Ala Phe Ser Gln

125

Tyr Leu Asn Arg Arg Gly Glu Val Leu Leu Asn Leu Lys Gly Gly Lys  
355 360 365

[illegible]



100

105

110

ccc tat aac gtt ttt tcc gat tgc ttc gcc gcc atg gcc ttt agt caa  
384

Pro Tyr Asn Val Phe Ser Asp Cys Phe Ala Ala Met Ala Phe Ser Gln  
115 120 125

tat gcc tta gcc agt ggg gcg cag gaa gct aaa gcc att gcc ctg cag  
432

Tyr Ala Leu Ala Ser Gly Ala Gln Glu Ala Lys Ala Ile Ala Leu Gln  
130 135 140

gcc tac aat aac gtc cta cgc cgt cag cac aat ccc aaa ggt caa tac  
480

Ala Tyr Asn Asn Val Leu Arg Arg Gln His Asn Pro Lys Gly Gln Tyr  
145 150 155 160

gag aag tcc tat cca ggt act aga ccc ctc aaa tcc ctg gcg gtg ccg  
528

Glu Lys Ser Tyr Pro Gly Thr Arg Pro Leu Lys Ser Leu Ala Val Pro  
165 170 175

atg att tta gcc aac ctc acc ctg gag atg gaa tgg tta tta ccg cct  
576

Met Ile Leu Ala Asn Leu Thr Leu Glu Met Glu Trp Leu Leu Pro Pro  
180 185 190

act acc gtg gaa gag gtg ttg gcc caa acc gtc aga gaa gtg atg acg  
624

Thr Thr Val Glu Glu Val Leu Ala Gln Thr Val Arg Glu Val Met Thr  
195 200 205

gat ttc ctc gac cca gaa ata gga tta atg cgg gaa gcg gtg acc ccc  
672

Asp Phe Leu Asp Pro Glu Ile Gly Leu Met Arg Glu Ala Val Thr Pro  
210 215 220

aca gga gaa ttt gtt gat agt ttt gaa ggg cgg ttg ctc aac cca gga  
720

Thr Gly Glu Phe Val Asp Ser Phe Glu Gly Arg Leu Leu Asn Pro Gly  
225 230 235 240

cac ggc att gaa gcc atg tgg ttc atg atg gac att gcc caa cgc tcc  
768

His Gly Ile Glu Ala Met Trp Phe Met Met Asp Ile Ala Gln Arg Ser  
245 250 255



ggc gat cgc cag tta cag gag caa gcc att gca gtg gtg ttg aac acc  
816

Gly Asp Arg Gln Leu Gln Glu Gln Ala Ile Ala Val Val Leu Asn Thr  
260 265 270

ctg gaa tat gcc tgg gat gaa gaa ttt ggt ggc ata ttt tat ttc ctt  
864

Leu Glu Tyr Ala Trp Asp Glu Glu Phe Gly Gly Ile Phe Tyr Phe Leu  
275 280 285

gat cgc cag ggc cac cct ccc caa caa ctg gaa tgg gac caa aag ctc  
912

Asp Arg Gln Gly His Pro Pro Gln Gln Leu Glu Trp Asp Gln Lys Leu  
290 295 300

tgg tgg gta cat ttg gaa acc ctg gtt gcc cta gcc aag ggc cac caa  
960

Trp Trp Val His Leu Glu Thr Leu Val Ala Leu Ala Lys Gly His Gln  
305 310 315 320

gcc act ggc caa gaa aaa tgt tgg caa tgg ttt gag cgg gtc cat gat  
1008

Ala Thr Gly Gln Glu Lys Cys Trp Gln Trp Phe Glu Arg Val His Asp  
325 330 335

tac gcc tgg agt cat ttc gcc gat cct gag tat ggg gaa tgg ttt ggc  
1056

Tyr Ala Trp Ser His Phe Ala Asp Pro Glu Tyr Gly Glu Trp Phe Gly  
340 345 350

tac ctg aat cgc cgg gga gag gtg tta ctc aac cta aaa ggg ggg aaa  
1104

Tyr Leu Asn Arg Arg Gly Glu Val Leu Leu Asn Leu Lys Gly Gly Lys  
355 360 365

tgg aaa ggg tgc ttc cac gtg ccc cga gct ctg tgg ctc tgt gcg gaa  
1152

Trp Lys Gly Cys Phe His Val Pro Arg Ala Leu Trp Leu Cys Ala Glu  
370 375 380

act ctc caa ctt ccg gtt agt  
1173

Thr Leu Gln Leu Pro Val Ser  
385 390

005280-12654950

<210> 3  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic DNA

<400> 3  
gtgtaagctt tctgtatggg gtgt  
24

<210> 4  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic DNA  
  
<400> 4  
gcagggatcc caaccaggca gcggaa  
26

<210> 5  
<211> 32  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic DNA

<400> 5  
tttatcgata ttaattaggg ggaatgaatg ag  
32

<210> 6  
<211> 33  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic DNA

<400> 6  
tttggatcct cattattccc cctgattttt gaa  
33

<210> 7  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic DNA

<400> 7  
taaatcgata tttgtatgat tgcccatcgc cgtcag  
36

<210> 8  
<211> 36  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Synthetic DNA

<400> 8  
aaaggatcct taactaaccg gaagttggag agtttc  
36

CCDS:100000.1